Moderna dans l'actualité
Développement de médicaments à base d'ARNm
Tamtam a trouvé 20 articles récents sur Moderna.
- Moderna’s Surprise Rally Defies Bears Amid New Vaccine Hopes
- Moderna’s Cancer Vaccine Win Fuels Broad Push Across Tumor Types
- The Melanoma Win Is Real, The Price Isn't - Moderna And MRNY Both Sell (NASDAQ:MRNA)
- Moderna (MRNA) Ascends While Market Falls: Some Facts to Note
- What Analysts Are Saying About Moderna Stock
- Moderna downgraded to neutral at UBS on questions over revenue growth
- Moderna just had its best day since October. Here's what's going on, and what analysts expect
- BofA Adjusts Price Target on Moderna to $24 From $21, Maintains Underperform Rating
- Why Moderna Shares Are Quietly Climbing Off the Lows
- Moderna stock price target raised to $24 from $21 at BofA Securities
- Moderna (MRNA): Reassessing Valuation After a Modest Share Price Rebound
- Moderna reaffirms 2025-26 guidance, eyes multiple vaccine, oncology, and rare disease launches
- Moderna issues shareholder letter under Regulation FD disclosure
- Moderna, Inc. Reports 2025 Achievements and 2026 Outlook
- Moderna, searching for a rebound, to seek approval of mRNA flu shot
- Moderna Submits Application for mRNA-Based Seasonal Flu Vaccine Approval
- Moderna seeks flu vaccine approvals; Neumora Alzheimer’s data
- Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
- Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
- Why Is Moderna (MRNA) Stock Rocketing Higher Today
Articles collectés par Tamtam et retenus lorsqu'ils portent sur l'entreprise, des plus récents aux plus anciens. Chacun renvoie à sa source.
Vous vendez à des entreprises comme Moderna ?
Tamtam trouve les entreprises qui correspondent à votre client idéal, analyse chaque compte et vous dit qui contacter, et quand.
Trouver des entreprises similaires